You are viewing the site in preview mode

Skip to main content

Advertisement

Table 3 Summary of studies of recurrence patterns of glioblastoma in the temozolomide era

From: Initial and cumulative recurrence patterns of glioblastoma after temozolomide-based chemoradiotherapy and salvage treatment: a retrospective cohort study in a single institution

Author Clinical target delineation and prescribed dose Analyzed recurrent patients Proportion of central recurrence
(year) CTV1 (initial field) CTV2 (boost field)
Brandes et al. [6] Enhanced tumor area according to preoperative imaging plus 2–3 cm None (identical with initial field) 79 72.2%a
60 Gy in 30 fractions
Milano et al. [7] Edema plus 2 cm Residual tumor/resection cavity plus 2–2.5 cm 39 80%b
46–50 Gy in 23–25 fractions
60 Gy in 30 fractions
Minniti et al. [8] Residual tumor/resection cavity plus 2 cm Residual tumor/resection cavity plus 1–2 cm 105 75.2%c
50 Gy in 25 fractions 60 Gy in 30 fractions
McDonald et al. [9] Edema plus 0.5–1.2 cm Residual tumor/resection cavity plus 0–1 cm 41 78%d
46–54 Gy in 23–30 fractions
60 Gy in 30 fractions
Dobelbower et al. [10] Primary tumor and surrounding edema plus 0.5 cm on postoperative imaging Residual tumor/resection cavity plus 0.5 cm 20 90%a
60Gy in 30 fractions
46 Gy in 23 fractions
Present Study Residual tumor/resection cavity plus 2 cm and edema Residual tumor/resection cavity plus 0 cm 21 66.7%
50–54 Gy in 25–30 fractions 60 Gy in 30 fractions
  1. CTV: clinical target volume.
  2. aThe term “central” was not actually used in the report. Instead, “in-field” recurrence was defined as 80% of the tumor recurrence residing within the prescribed 95% isodose surface.
  3. bCentral recurrence was defined as growth of the original tumor or arising tumor(s) from the resection cavity.
  4. cCentral recurrence was defined as more than 95% of the recurrence volume within the 95% isodose line of 60 Gy.
  5. dCentral recurrence was defined as more than 95% of the recurrence volume inside the 100% isodose line of 60 Gy.